Filing Flows › Adaptive Biotechnologies (ADPT) › Q2 2026
Adaptive Biotechnologies (ADPT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Adaptive Biotechnologies (ADPT) reported revenue of $71.6M for the second quarter 2026 (Q2 2026), +22% from a year earlier and +1% from the quarter before. Operating margin was -22.0%, net loss $39.9M (55.8% of revenue).
Adaptive Biotechnologies, Q2 2026: revenue $71.6M (+22% year over year), operating margin -22.0%, net loss $39.9M, operating cash flow −$6.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $71.6M | +1% | +22% |
| Operating profit | −$15.8M | — | — |
| Net earnings | −$39.9M | — | — |
| Operating cash flow | −$6.4M | — | — |
What changed
Revenue was $71.6M in Q2 2026, up 22% year over year and up 1% from the previous quarter.
Operating costs exceeded revenue by $15.8M, an operating margin of -22.0%. Total costs grew 4% against revenue growth of 22%. The fastest-growing cost line was General & admin (+19%). The quarter ended with a net loss of $39.9M, wider than the previous quarter's $20.0M loss. Minority interests bore $153K of it: to shareholders the quarter was a loss of $39.8M. Net interest and other expense of $24.2M was the main reason.
Operating cash flow was −$6.4M. Non-cash charges added back $3.7M of depreciation and amortization and $11.1M of share-based compensation. Working capital and other items added $18.7M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$7.6M.
Questions
What was Adaptive Biotechnologies' revenue in the second quarter 2026?
Adaptive Biotechnologies (ADPT) reported revenue of $71.6M for the second quarter 2026 (Q2 2026), +22% from a year earlier and +1% from the quarter before.
Was Adaptive Biotechnologies profitable in the second quarter 2026?
Operating loss was $15.8M (-22.0% of revenue) and net loss $39.9M.